Fluoroquinolone-Resistant Pseudomonas aeruginosa: Assessment of Risk Factors and Clinical Impact

American Journal of Medicine

Volumn 119, Issue 6, 2006, Pages

  Gasink, Leanne B ^a   Fishman, Neil O ^a   Weiner, Mark G ^a   Nachamkin, Irving ^a   Bilker, Warren B ^a   Lautenbach, Ebbing ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Fluoroquinolones; Pseudomonas aeruginosa; Resistance

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL CHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ACADEMIC MEDICAL CENTERS; CASE-CONTROL STUDIES; COHORT STUDIES; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MULTIVARIATE ANALYSIS; ODDS RATIO; OFLOXACIN; PENNSYLVANIA; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33646912478     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.11.029     Document Type: Article

References (34)

1. Fluit A.C., Jones M.E., Schmitz F.J., Acar J., Gupta R., and Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 30 (2000) 454-460
2. Pfaller M.A., Jones R.N., Doern G.V., and Kugler K. Bacterial pathogens isolated from patients with bloodstream infection. frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 42 (1998) 1762-1770
3. Kang C.I., Kim S.H., Kim H.B., et al. Pseudomonas aeruginosa bacteremia. risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 37 (2003) 745-751
4. Obritsch M.D., Fish D.N., MacLaren R., and Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 48 (2004) 4606-4610
5. Andrade S.S., Jones R.N., Gales A.C., and Sader H.S. Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres. 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). J Antimicrob Chemother 52 (2003) 140-141
6. Neuhauser M.M., Weinstein R.A., Rydman R., Danziger L.H., Karam G., and Quinn J.P. Antibiotic resistance among gram-negative bacilli in US intensive care units. implications for fluoroquinolone use. JAMA 289 (2003) 885-888
7. Paladino J.A., Sunderlin J.L., Forrest A., and Schentag J.J. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa. J Antimicrob Chemother 52 (2003) 457-463
8. Krcmery V., Mateika F., Krupova I., Trupl J., and Kunova A. Bacteremia due to ciprofloxacin resistant Pseudomonas aeruginosa in cancer patients. risk factors for resistance and outcome of 25 episodes. Infect Dis Clin Pract 8 (1999) 158-161
9. Hsu D.I., Okamoto M.P., Murthy R., and Wong-Beringer A. Fluoroquinolone-resistant Pseudomonas aeruginosa. risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 55 (2005) 535-541
10. Barton T., Fishman N.O., Weiner M.G., LaRosa L., and Lautenbach E. High rate of coadministration of di- or tri-valent cation-containing compounds with oral fluoroquinolones. risk factors and potential implications. Infect Control Hosp Epidemiol 26 (2005) 69-76
11. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992) 613-619
12. National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing. Eleventh Informational Supplement (2001), National Committee for Clinical Laboratory Standards, Wayne, PA NCCLS document M100-S11
13. National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing: Tenth Informational Supplement. NCCLS document M100-S10 (2000), National Committee for Clinical Laboratory Standards, Wayne, PA
14. Armitage P. Test for linear trend in proportions and frequencies. Biometrics 11 (1955) 375-386
15. Kleinbaum D.G., Kupper L.L., and Morgenstern H. Epidemiologic Research. Principles and Quantitative Methods (1982), Van Nostrand Reinhold, New York
16. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (1959) 719-748
17. Hosmer D.O., and Lemeshow S.L. Applied Logistic Regression (1989), Wiley and Sons, New York
18. Harris A.D., Karchmer T.B., Carmeli Y., and Samore M.H. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance. a systematic review. Clin Infect Dis 32 (2001) 1055-1061
19. Sun J. A non-parametric test for interval censored failure time data with applications to AIDS studies. Stat Med 15 (1996) 1387-1395
20. Mickey R.M., and Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 129 (1989) 125-137
21. Cosgrove S.E., and Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 36 (2003) 1433-1437
22. Chen D.K., McGeer A., de Azavedo J.C., Low D.E., and Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 341 (1999) 233-239
23. Lautenbach E., Fishman N.O., Bilker W.B., et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 162 (2002) 2469-2477
24. Polk R.E., Johnson C.K., McClish D., Wenzel R.P., and Edmond M.B. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 39 (2004) 497-503
25. Zervos M.J., Hershberger E., Nicolau D.P., et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 37 (2003) 1643-1648
26. Carmeli Y., Troillet N., Eliopoulos M., and Samore M. Emergence of antibiotic-resistant Pseudomonas aeruginosa. comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 43 (1999) 1379-1382
27. El Amari E.B., Chamot E., Auckenthaler R., Pechere J.C., and Van Delden C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 33 (2001) 1859-1864
28. Krcmery V., Mateicka F., Krupova I., Trupl J., Kunova A., and A case-control study. Bacteremia due to ciprofloxacin-resistant Pseudomonas aeruginosa in cancer patients. risk factors for resistance and outcome of 25 episodes. Infect Dis Clin Pract 8 (1999) 158-161
29. Lautenbach E., Strom B.L., Bilker W.B., Patel J.B., Edelstein P.H., and Fishman N.O. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum Β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 33 (2001) 1288-1294
30. Paramythiotou E., Lucet J.C., Timsit J.F., et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units. role of antibiotics with antipseudomonal activity. Clin Infect Dis 38 (2004) 670-677
31. Defez C., Fabbro-Peray P., Bouziges N., et al. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect 57 (2004) 209-216
32. Piddock L.J.V. Mechanisms of resistance to fluoroquinolones. state-of-the-art 1992-1994. Drugs 49 Suppl 2 (1995) 29-35
33. Vidal F., Mensa J., Almela M., et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 156 (1996) 2121-2126
34. Harris A.D., Karchmer T.B., Carmeli Y., and Samore M.H. Methodological principles of case-control studies that anlayzed risk factors for antibiotic resistance. a systematic review. Clin Infect Dis 32 (2001) 1055-1061